Chemistry:Gestonorone acetate
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Other names | Gestronol acetate; Norhydroxyprogesterone acetate; 17α-Hydroxy-19-norprogesterone 17α-acetate; 17α-Acetoxy-19-norprogesterone; 17α-Hydroxy-19-norpregn-4-ene-3,20-dione 17α-acetate |
| Drug class | Progestin; Progestogen |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C22H30O4 |
| Molar mass | 358.478 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Gestonorone acetate, or gestronol acetate, also known as norhydroxyprogesterone acetate, is a progestin of the 19-norprogesterone and 17α-hydroxyprogesterone groups which was developed in the early 1960s but was never marketed.[1][2][3][4][5][6][7][8][9][10][11][12][13][14] It is the C17α acetate ester of gestronol (17α-hydroxy-19-norprogesterone).
Gestonorone acetate has been found to consistently inhibit ovulation at an oral dosage of 10 mg/day in combination with 50 μg/day oral ethinylestradiol.[15] Weak or no endometrial effects were observed at an oral dosage of 100 mg/day, basal vacuoles appeared at 130 to 140 mg/day, and full endometrial secretory transformation occurred at 220 mg/day.[16]
See also
References
- ↑ "Steroids. XX. Hydrolysis of steroidal esters by malt enzyme. 1. Selective hydrolysis of steroidal acetates". Yakugaku Zasshi 81 (3): 369–373. 1961. doi:10.1248/yakushi1947.81.3_369. ISSN 0031-6903.
- ↑ "Steroids. XXIII Hydrolysis of steroidal esters by malt enzyme. 4. Synthesis of 17α,19-dihydroxyprogesterone and 17α-hydroxy-19-norprogesterone". Yakugaku Zasshi 81 (3): 381–384. 1961. doi:10.1248/yakushi1947.81.3_381. ISSN 0031-6903.
- ↑ "Steroid anti-estrogens". Steroids 1 (2): 185–209. 1963. doi:10.1016/S0039-128X(63)80136-1. ISSN 0039-128X.
- ↑ "Pregnancy-maintaining effect of synthetic progestogens in the rat". Acta Endocrinologica 42 (4): 533–536. April 1963. doi:10.1530/acta.0.0420533. PMID 13979052.
- ↑ "Steroids. CXCVI. 19-Norsteroids. III. Synthesis of 19-norprogesterones". Helvetica Chimica Acta 46: 1017–1029. 1963. doi:10.1002/hlca.19630460332. ISSN 0018-019X.
- ↑ "[Experimental viewpoints in the testing of synthetic gestagens]". Deutsche Medizinische Wochenschrift 88 (13): 629–638. March 1963. doi:10.1055/s-0028-1111990. PMID 13958089.
- ↑ "Orally active steroidal ovulation inhibitors in the adult estrus rabbit". Steroids 2 (5): 521–525. 1963. doi:10.1016/0039-128X(63)90029-1. ISSN 0039-128X.
- ↑ "Inhibition of ovulation by steroids". Journal of the Egyptian Medical Association 1962-1963: 67–73. 1963. ISSN 0013-2411.
- ↑ "The pharmacology of new gestational and anabolic steroids". Deutsch-Englische Medizinische Rundschau 1 (4): 385–399. 1962. ISSN 0003-3332.
- ↑ "Relationship Between Progestational Activity and Chemical Structure of Synthetic Steroids". The Journal of Endocrinology 30 (2): 159–170. September 1964. doi:10.1677/joe.0.0300159. PMID 14207040.
- ↑ "Inhibition of ovulation determined by estimation of pregnanediol excretion". International Journal of Fertility 9: 57–67. 1964. PMID 14106269. https://www.popline.org/node/473877.
- ↑ "[The effect of various gestagens on the development of the fetus and rate of mortality in animal experiments]". Archiv Fur Gynakologie 204 (1): 68–77. 1967. doi:10.1007/BF00668265. PMID 5630697.
- ↑ "The progestational and anti-estrogenic activities of some novel 11beta-substituted steroids". Steroids 23 (4): 585–602. April 1974. doi:10.1016/0039-128X(74)90010-5. PMID 4829347.
- ↑ "Stereoselective asymmetric synthesis and characterization of 17α-acetyoxy-19-nor-progesterone". Journal of Central South University of Technology 11 (3): 300–303. 2004. doi:10.1007/s11771-004-0061-y. ISSN 1005-9784.
- ↑ The Control of Fertility. Elsevier. 3 September 2013. pp. 222–. ISBN 978-1-4832-7088-3. https://books.google.com/books?id=ehQlBQAAQBAJ&pg=PA222.
- ↑ "Die gestagene Wirkung von Hydroxy-nor-Progesteronestern bei der Frau". Gewebs- und Neurohormone. Symposion der Deutschen Gesellschaft für Endokrinologie. Springer. 1962. pp. 248–255. doi:10.1007/978-3-642-86860-3_27. ISBN 978-3-540-02909-0. "Nach oraler Verabreichung von 100 mg des Hydroxy-nor-ProgesteronAcetats sah man nur schwache oder noch keine gestagene Wirkung am Endometrium (Abb. 3). Nach der oralen Dosis von 130- 140 mg traten basale Vacuolen auf, nach 220 mg war - außer bei einer Patientin mit individuell geringerer Ansprechbarkeit des Endometriums (2) - eine volle sekretorische Umwandlung erreicht: [...]"
 |  |
